Key facts, as of
As of September 29, 2026, Edwards Lifesciences (EW) trades at $88.08, up 14.1% over the past year. Its 52-week range runs from $72.30 to $96.29; the price is 8.5% below that high. It sits 3.5% above its 200-day average of $85.10, the usual sign of a long-term uptrend. Its 30-day volatility is 25.6% annualized, which we rate medium risk. It has a trailing P/E of 52.4.
Cite: Portfolio Terminal, "Edwards Lifesciences (EW) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/ew
Where it trades today
trading 66% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- EW trades at 52.4x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- EW carries a beta of 0.85, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- EW is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in EW.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
Methodology
- Price, market cap, beta, yield, and liquidity fields for EW come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for EW. Last refresh: Sep 29, 2026, 10:33 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Edwards Lifesciences does
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a…
What analysts expect
EW carries a buy consensus from 26 analysts, with an average price target of $100.96 versus $88.08 today (+14.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
EW generated $6.51B in trailing revenue (13.6% year over year), with a 15.4% net margin, and $1.23B of free cash flow, supported by $3.55B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $6.07B | $4.73B | $1.64B | $1.07B | $1.84 | $1.33B |
| 2024 | $5.44B | $4.32B | $1.48B | $4.17B | $6.98 | $259.90M |
| 2023 | $5.01B | $4.03B | $1.49B | $1.40B | $2.31 | $629.50M |
| 2022 | $4.46B | $3.74B | $1.54B | $1.52B | $2.46 | $953.40M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
EW beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 0.4% below its 50-day average and 3.5% above its 200-day.
- RSI at 50 is neither stretched nor washed out.
- The nearest ceiling is $89.26 (+1.3%), the nearest floor $87.39 (-0.8%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is EW a good buy right now?
Edwards Lifesciences trades at 52.4x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 25.6% volatility.
Does EW pay dividends?
Edwards Lifesciences does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is EW?
With 30-day annualized volatility of 25.6% and beta of 0.85, EW is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for EW?
The average analyst price target for Edwards Lifesciences (EW) is $100.96 based on 26 analyst estimates, about 14.6% above the current price of $88.08. The published range runs from $84.00 to $110.00.
How much revenue does EW generate?
Edwards Lifesciences reported $6.51B in trailing twelve-month revenue. Revenue growth is running at 13.6% year over year. Net margin sits at 15.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare EW with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.